Privium Fund Management B.V. Taysha Gene Therapies, Inc. Transaction History
Privium Fund Management B.V.
- $469 Million
- Q2 2025
A detailed history of Privium Fund Management B.V. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 134,900 shares of TSHA stock, worth $619,191. This represents 0.07% of its overall portfolio holdings.
Number of Shares
134,900
Previous 134,900
-0.0%
Holding current value
$619,191
Previous $187,000
66.31%
% of portfolio
0.07%
Previous 0.05%
Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
154Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$115 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$108 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$99.6 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$77.4 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$57.8 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $222M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...